iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance.
Products, services, technology
IOA-244: a next generation PI3Kδ inhibitor.
IOA-289: a novel autotaxin (ATX) inhibitor.
iOnctura also has an early pipeline of antibody candidates.
We innovate, through pioneering scientific research, in collaboration with world renowned collaborators to develop selective therapies against targets of interest to us.